Forest's Bystolic Gets Unanimous Thumbs-Down
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest's beta blocker Bystolic suffered a resounding defeat when FDA's Cardio-Renal advisory committee unanimously recommended that the agency not approve it to treat chronic heart failure.